Abstract:Purpose: This study aimed to explore novel targets for hepatocellular carcinoma (HCC) treatment by investigating the role of fatty acid metabolism. Methods: RNA-seq and clinical data of HCC were obtained from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Bioinformatic analyses were employed to identify differentially expressed genes (DEGs) related to prognosis. A signature was then constructed using the Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression to classify HCC patients from the TCGA database into low-risk and high-risk groups. The predictive performance of the signature was evaluated through principal components analysis (PCA), Kaplan Meier (KM) survival analysis, receiver operating characteristics (ROC) curves, nomogram, genetic mutations, drug sensitivity analysis, immunological correlation analysis, and enrichment analysis. Single-cell maps were constructed to illustrate the distribution of core genes. Immunohistochemistry (IHC), quantitative real-time PCR (qRT-PCR), and western blot were employed to verify the expression of core genes. The function of one core gene was validated through a series of in vitro assays, including cell viability, colony formation, wound healing, trans-well migration, and invasion assays. The results were analyzed in the context of relevant signaling pathways. Results: Bioinformatic analyses identified 15 FAMGs that were related to prognosis. A 4-gene signature was constructed, and patients were divided into high- and low-risk groups according to the signature. The high-risk group exhibited a poorer prognosis compared to the low-risk group in both the training (P < 0.001) and validation (P = 0.020) sets. Furthermore, the risk score was identified as an independent predictor of OS (P < 0.001, HR = 8.005). The incorporation of the risk score and clinicopathologic features into a nomogram enabled the effective prediction of patient prognosis. The model was able to effectively predict the immune microenvironment, drug sensitivity to chemotherapy, and gene mutation for each group. Single-cell maps demonstrated that FAMGs in the model were distributed in tumor cells. Enrichment analyses revealed that the cell cycle, fatty acid β oxidation and PPAR signaling pathways were the most significant pathways. Among the four key prognostically related FAMGs, Spermine Synthase (SMS) was selected and validated as a potential oncogene affecting cell cycle, PPAR-γ signaling pathway and fatty acid β oxidation in HCC. Conclusions: The risk characteristics based on FAMGs could serve as independent prognostic indicators for predicting HCC prognosis and could also serve as evaluation criteria for gene mutations, immunity, and chemotherapy drug therapy in HCC patients. Meanwhile, targeted fatty acid metabolism could be used to treat HCC through related signaling pathways.

ARHGEF39 targeted by E2F1 fosters hepatocellular carcinoma metastasis by mediating fatty acid metabolism

LncRNA AY promotes hepatocellular carcinoma metastasis by stimulating ITGAV transcription.

Expression of Rho Guanine Nucleotide Exchange Factor 39 (ARHGEF39) and Its Prognostic Significance in Hepatocellular Carcinoma.

FGF 19 Promotes Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells by Modulating the GSK 3 Β / Β-Catenin Signaling Cascade Via FGFR 4 Activation

A Negative Feedback Loop Between KLF9 and the EMT Program Dictates Metastasis of Hepatocellular Carcinoma.

The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis

Calcium-Binding Protein 39 Promotes Hepatocellular Carcinoma Growth and Metastasis by Activating Extracellular Signal-Regulated Kinase Signaling Pathway

Fatty acid metabolism affects hepatocellular carcinoma progression via the PPAR-γ signaling pathway and fatty acid β-oxidation

DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis

Cancer-associated Fibroblasts Contributed to Hepatocellular Carcinoma Recurrence and Metastasis Via CD36-mediated Fatty-Acid Metabolic Reprogramming.

ARHGEF37 overexpression promotes extravasation and metastasis of hepatocellular carcinoma via directly activating Cdc42

ARHGEF11 Promotes Proliferation and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Through Activation of &Amp;#x3b2;-Catenin Pathway

E2F1‐mediated AUF1 Upregulation Promotes HCC Development and Enhances Drug Resistance Via Stabilization of AKR1B10

HIF-1α and HDAC1 Mediated Down-Regulation of FAM99A Contributes to Hypoxia Induced HCC Metastasis

Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4

E2F1 As a Potential Prognostic and Therapeutic Biomarker by Affecting Tumor Development and Immune Microenvironment in Hepatocellular Carcinoma.

Expression and Roles of Fatty Acid Synthase in Hepatocellular Carcinoma

FGF19/FGFR4-mediated Elevation of ETV4 Facilitates Hepatocellular Carcinoma Metastasis by Upregulating PD-L1 and CCL2

EYA1 promotes cell migration and tumor metastasis in hepatocellular carcinoma.

Clinical Implication of E2F Transcription Factor 1 in Hepatocellular Carcinoma Tissues

Fibronectin 1 derived from tumor-associated macrophages and fibroblasts promotes metastasis through the JUN pathway in hepatocellular carcinoma